BriaCell Therapeutics Corp. (BCT.TO) TSX

6.74

-8.48(-55.72%)

Updated at January 14 04:00PM

Currency In CAD

BriaCell Therapeutics Corp.

Address

Bellevue Centre

West Vancouver, BC V7T 2X1

Canada

Phone

604-921-1810

Sector

Healthcare

Industry

Biotechnology

Employees

16

First IPO Date

August 13, 2012

Key Executives

NameTitlePayYear Born
William V. WilliamsChief Executive Officer, President & Director980,8981955
Charles Louis WisemanFounder, Principal Research Advisor & Member of Scientific Advisory Board332,3361946
Miguel A. Lopez-LagoChief Scientific Officer616,8091970
Giuseppe Del PrioreChief Medical Officer679,5191962
Gadi LevinChief Financial Officer & Corporate Secretary737,8351973

Description

BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.